IMMUNOMODULATORY RESPONSE TO NEOADJUVANT NIVOLUMAB IN NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA: RESULTS FROM A PHASE I TRIAL

被引：0
|
作者：
Singla, Nirmish
Nirschl, Thomas
Obradovic, Aleksandar
Shenderov, Eugene
Lombardo, Kara
Liu, Xiaopu
Pons, Alice
Zarif, Jelani
Rowe, Steven
Trock, Bruce
Hammers, Hans
Bivalacqua, Trinity
Pierorazio, Phillip
Deutsch, Julie
Lotan, Tamara
Taube, Janis
Ged, Yasser
Gorin, Michael
Allaf, Mohamad
Drake, Charles
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD43-05
引用
收藏
页码：E1119 / E1120
页数：2
相关论文
共 50 条
  • [1] Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
    Singla, Nirmish
    Nirschl, Thomas R.
    Obradovic, Aleksandar Z.
    Shenderov, Eugene
    Lombardo, Kara
    Liu, Xiaopu
    Pons, Alice
    Zarif, Jelani C.
    Rowe, Steven P.
    Trock, Bruce J.
    Hammers, Hans J.
    Bivalacqua, Trinity J.
    Pierorazio, Phillip M.
    Deutsch, Julie S.
    Lotan, Tamara L.
    Taube, Janis M.
    Ged, Yasser M. A.
    Gorin, Michael A.
    Allaf, Mohamad E.
    Drake, Charles G.
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [2] Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
    Nirmish Singla
    Thomas R. Nirschl
    Aleksandar Z. Obradovic
    Eugene Shenderov
    Kara Lombardo
    Xiaopu Liu
    Alice Pons
    Jelani C. Zarif
    Steven P. Rowe
    Bruce J. Trock
    Hans J. Hammers
    Trinity J. Bivalacqua
    Phillip M. Pierorazio
    Julie S. Deutsch
    Tamara L. Lotan
    Janis M. Taube
    Yasser M. A. Ged
    Michael A. Gorin
    Mohamad E. Allaf
    Charles G. Drake
    Scientific Reports, 14
  • [3] Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
    Singla, Nirmish
    Nirschl, Thomas
    Obradovic, Aleksandar
    Shenderov, Eugene
    Lombardo, Kara A.
    Liu, Xiaopu
    Pons, Alice
    Zarif, Jelani
    Rowe, Steven P.
    Trock, Bruce J.
    Hammers, Hans J.
    Bivalacqua, Trinity
    Pierorazio, Phillip
    Deutsch, Julie S.
    Lotan, Tamara L.
    Taube, Janis M.
    Ged, Yasser
    Gorin, Michael A.
    Allaf, Mohamad E.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] PHASE II TRIAL OF NEOADJUVANT AXITINIB IN PATIENTS WITH LOCALLY ADVANCED NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA
    Karam, Jose
    Devine, Catherine
    Urbauer, Diana
    Lozano, Marisa
    Maity, Tapati
    Ahrar, Kamran
    Tamboli, Pheroze
    Tannir, Nizar
    Wood, Christopher
    JOURNAL OF UROLOGY, 2014, 191 (04): : E646 - E646
  • [5] Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.
    Bilen, Mehmet Asim
    Liu, Yuan
    Nazha, Bassel
    Brown, Jacqueline T.
    Osunkoya, Adeboya O.
    Williams, Sierra
    Session, Wilena
    Yantorni, Lauren Beth
    Russler, Greta
    Caulfield, Sarah
    Joshi, Shreyas S.
    Narayan, Vikram M.
    Filson, Christopher Paul
    Ogan, Kenneth
    Kucuk, Omer
    Carthon, Bradley Curtis
    Kissick, Haydn
    Master, Viraj A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [6] A URINARY PROTEOMICS ANALYSIS OF PATIENTS TREATED WITH NEOADJUVANT AXITINIB FOR NON-METASTATIC CLEAR-CELL RENAL-CELL CARCINOMA: ANALYSIS FROM A PHASE II TRIAL
    McIntosh, Andrew
    Wang, Hong
    Umbreit, Eric
    Suk-Ouichai, Chalairat
    Gonzalez, Graciela Nogueras
    Matulay, Justin
    Wood, Christopher
    Hanash, Samir
    Karam, Jose
    JOURNAL OF UROLOGY, 2019, 201 (04): : E295 - E296
  • [7] Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
    Motzer, Robert J.
    Rini, Brian I.
    McDermott, David F.
    Redman, Bruce G.
    Kuzel, Timothy M.
    Harrison, Michael R.
    Vaishampayan, Ulka N.
    Drabkin, Harry A.
    George, Saby
    Logan, Theodore F.
    Margolin, Kim A.
    Plimack, Elizabeth R.
    Lambert, Alexandre M.
    Waxman, Ian M.
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1430 - 1437
  • [8] Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial
    Fitzgerald, Kelly N.
    Lee, Chung-Han
    Voss, Martin H.
    Carlo, Maria I.
    Knezevic, Andrea
    Peralta, Laura
    Chen, Yingbei
    Lefkowitz, Robert A.
    Shah, Neil J.
    Owens, Colette N.
    Mchugh, Deaglan J.
    Aggen, David H.
    Laccetti, Andrew L.
    Kotecha, Ritesh R.
    Feldman, Darren R.
    Motzer, Robert J.
    EUROPEAN UROLOGY, 2024, 86 (02) : 90 - 94
  • [9] A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).
    Zhang, Shun
    Ji, Changwei
    Liu, Guangxiang
    Guo, Hongqian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 420 - 420
  • [10] Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
    Choueiri, Toni K.
    Fishman, Mayer N.
    Escudier, Bernard
    McDermott, David F.
    Drake, Charles G.
    Kluger, Harriet
    Stadler, Walter M.
    Perez-Gracia, Jose Luis
    McNeel, Douglas G.
    Curti, Brendan
    Harrison, Michael R.
    Plimack, Elizabeth R.
    Appleman, Leonard
    Fong, Lawrence
    Albiges, Laurence
    Cohen, Lewis
    Young, Tina C.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Srivastava, Shivani
    Jure-Kunkel, Maria
    Kurland, John F.
    Simon, Jason S.
    Sznol, Mario
    CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5461 - 5471
12345